# Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

> **NCT02810418** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Neoplasms
- Pancreatic Neoplasms

## Interventions

- **DRUG:** LMB-100
- **DRUG:** Nab-Paclitaxel
- **DEVICE:** Mesothelin Expression
- **DRUG:** LMB-100

## Key facts

- **NCT ID:** NCT02810418
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-03
- **Primary completion:** 2019-01-02
- **Final completion:** 2021-06-22
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02810418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02810418, "Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02810418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*